R&D Antibodies

Innovative Leaders in Immunoassay and Immunotherapy Technologies

Research & Diagnostic Antibodies seeks to commercialize our PliNOSa® test, the first accurate and reliable in vitro diagnostic (IVD) test for the early detection of sepsis, and our aSeptiMab® therapy, a first-in-class immunotherapeutic to effectively treat sepsis.

Our research team discovered and patented a novel blood biomarker to predict the onset of sepsis pathology, enabling clinicians to launch effective, life-saving interventions.  This new sepsis biomarker is inducible nitric oxide synthase (iNOS), an intracellular enzyme not normally found in plasma. Our novel IVD test, PliNOSa®, is a chemiluminescent double monoclonal antibody sandwich enzyme immunoassay (EIA) for plasma iNOS. During clinical studies the PliNOSa® test demonstrated significant diagnostic sensitivity and specificity for the early detection of the onset of sepsis pathology. Our research team also screened our panel of 24 anti-iNOS monoclonal antibodies for their individual in vivo neutralizing activity and found five that could stop the progression of the sepsis pathology. This led to the development of aSeptiMab®, our candidate humanized anti-iNOS monoclonal antibody immunotherapeutic to effectively treat sepsis.